Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

6

punsarn.item.page.citation

Chan A.T.C., Lee V.H.F., Hong R.L., Ahn M.J., Chong W.Q., Kim S.B., Ho G.F., Caguioa P.B., Ngamphaiboon N., Ho C., Aziz M.A.S.A., Ng Q.S., Yen C.J., Soparattanapaisarn N., Ngan R.K.C., Kho S.K., Tiambeng M.L.A., Yun T., Sriuranpong V., Algazi A.P., Cheng A., Massarelli E., Swaby R.F., Saraf S., Yuan J., Siu L.L. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Annals of Oncology Vol.34 No.3 (2023) , 251-261. 261. doi:10.1016/j.annonc.2022.12.007 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82374

item.page.availability

Collections